Durolane is a device, methylprednisolone in a drug
Devicesingle intraarticular injection
Other names: Durolane and Depo-Medrol are the brand names
NCT Number: NCT01209364
The primary objective is to determine whether Durolane is non-inferior to methylprednisolone, as assessed by level of pain, when each are given as single intra-articular injections for the relief of pain, in the treatment of symptomatic osteoarthritis of the knee at 12 weeks.
Looking for future studies?
Notify Me35 year–80 year
All sexes
Interventional
Phase 3
Alberta Bone & Joint Health Institute, Calgary, Alberta, Canada
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
single intraarticular injection
Other names: Durolane and Depo-Medrol are the brand names
Time frame: up to 12 weeks
Time frame: 26 weeks blinded phase + 26 weeks OLE
Will be assessed at each clinic visit
Time frame: 26 weeks blinded phase + 26 weeks OLE
Will be assessed at each clinic visit
Time frame: 26 weeks blinded phase + 26 weeks OLE
Will be assessed at each clinic visit
Time frame: 26 weeks blinded phase + 26 weeks OLE
Will be assessed at each clinic visit using standard questions
Galderma R&D
Industry
Double-Blind, Randomized, Parallel Group, Multicenter Study of Durolane Compared to Methylprednisolone in Subjects With Osteoarthritis of the Knee
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07327190
Arthritis, Joint Diseases
Kütahya, Turkey (Türkiye)
View Trial DetailsNCT04492670
Arthritis, Joint Diseases
Hong Kong
View Trial DetailsNCT04653896
Arthritis, Joint Diseases
The Bronx, New York, United States
View Trial DetailsNCT07717957
Arthritis, Joint Diseases
Kuantan, Pahang, Malaysia
View Trial Details